PharmaCyte Biotech, Inc. PMCB
NASDAQ
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -1,334.66% | -163.36% | -116.20% | -131.19% | -104.18% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 456.33% | 146.30% | 91.50% | 106.91% | 87.33% |
| Change in Net Operating Assets | -518.38% | -242.13% | 121.81% | 948.12% | 233.87% |
| Cash from Operations | 14.33% | -73.01% | -111.40% | -133.41% | -60.37% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 128.57% | 128.57% | 75.00% | 100.00% |
| Cash from Investing | -- | 128.57% | 128.57% | 75.00% | 100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 77.69% | 84.20% | 83.83% | 89.34% | 27.49% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | 99.34% | 99.62% | 100.00% | 89.35% | 51.53% |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 143.74% | 126.30% | 118.51% | 105.41% | 45.29% |
| Foreign Exchange rate Adjustments | 675.00% | 1,100.00% | 323.08% | -190.00% | 42.86% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 123.44% | 109.80% | 108.44% | 89.67% | 53.70% |